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Dear Editor,
Perianal involvement is one of the most important manifes-
tations of Crohn’s disease (CD), and it affects up to 30–40%
of these patients. Usually, CD affects young patients and it
is associated to high morbidity and negative impact in the
quality of life. The clinical treatment has been improved in
the last decade with the large use of immunosuppressant
drugs and the advent of monoclonal antibodies, such as the
anti-TNF- (anti-tumor necrosis factor alfa). The best results
in the treatment of perianal CD depend on the appropriate
drug management and surgical approach.1 The boundaries
between medical treatment, which involves the management
of increasingly speciﬁc drugs, and surgery are not easy to
establish. The association of both is better than isolated thera-
pies, mainly for complex ﬁstulazing perianal CD. This is due to
the fact that CD is a chronic, recurrent disease whose etiology
is not fully elucidated. For this reason, surgical indications are
restricted to the treatment of the disease’s complications and
its clinical intractability.
About 70–80% of patients will undergo a surgical proce-
dure during their follow-up, and perianal surgical procedures
are part of those surgeries. The surgery does not promote
the cure of the disease and therefore the decision to operate
can be difﬁcult and depends on the surgeon’s experience in
handling this type of condition. Best clinical management has
inﬂuenced the timing of surgical indication, delaying or even
avoiding it. However, it is still a conﬂicting issue and more
prospective studies are required. Relapse of CD after surgery
may occur in patients considered to be high risk, such as
being young at the onset of the disease, smoking habits, fam-
ily history of CD, and ﬁstulizing phenotype. In this sense, the
decision for surgery depends on the aggressiveness of the peri-
anal CD and the concomitant involvement of the colon and/or
small intestine. Furthermore, it is important to establish CD
phenotypes, which can be inﬂammatory, stenotic and/or ﬁs-
tulizing. The ﬁstulizing form of the disease is related to higher
incidence of recurrence and indicates its progression.Indication for surgery, concerning perianal CD, includes the
presence of abscesses and ﬁstulas that remain active even
with the use of immunosuppressant and/or biological therapy.Preoperative imaging studies, such as magnetic resonance
imaging (MRI) of the anal canal and/or endoanal ultrasonogra-
phy, can help identify abscesses which are sometimes smaller
and deeper, but symptomatic. They can also delimit the loca-
tion of the abscesses in relation to the anal sphincters and the
involved portion of the anal canal.2 Additionally, these exams
allow the identiﬁcation of the course of perianal ﬁstulas,
showing the degree of involvement of the sphincter muscles.
Endoanal ultrasonography is limited in cases of severe steno-
sis of the anal canal, which makes it impossible to introduce
the device.
Perineal examination under anesthesia and surgical proce-
dures should consist of draining abscesses and exploration of
ﬁstulas by placing seton, which can remain for a long period.
Fistulotomy without repairs should be restricted to very shal-
low paths that do not compromise the sphincter muscles.
Another option to consider is the endorectal advancement
ﬂap, which has been used in the treatment of complex or
recurrent ﬁstulas, and healing is observed in 60–70% of CD
patients.3
The use of ﬁbrin glue in the treatment of CD perianal ﬁstula
showed efﬁcacy in the treatment of complex ﬁstulas, but no
advantages in the case of simple ﬁstulas when compared to
conventional treatment.4 Fibrin glue seems to be less effective
in patients with CD, but is well tolerated and has a minimal
risk proﬁle, and could be used to avoid further surgery or as
an alternative to long-term seton placement. The ﬁstula plug
is another treatment option that has been studied for peri-
anal ﬁstula. It is a portion of lyophilized porcine intestinal
submucosa and acts as a collagen scaffold, which is ﬁlled by
endogenous cells. Reported healing rates were 54.3% in CD
patients at follow-up between 3 and 24 months, which did not
differ from patients without CD. The extrusion of the plug is
the main reason for secondary failure of this technique.5
Mesenchymal stem cell (MSC) therapy for CD represents a
promising strategy and has been studied for luminal disease.6
To assess the efﬁcacy of MSCs for CD-related ﬁstulas, the
ADMIRE-Crohn’s disease multicentre study is underway
(http://www.clinicaltrials.gov/ct2/show/NCT01541579). This
protocol evaluates the use of adipose derived mesenchy-
mal  stem cells (administered by intralesional injection) for

























6j coloproctol (rio j). 
nduction of remission in perianal ﬁstulizing CD, and the
stimated primary completion date is the beginning of the
ext year with promising results. The main advantage of this
echnique is the sphincter preservation, avoiding repairs or
stulotomy.
Not infrequently, perianal ﬁstulas are accompanied by
xtensive CD involvement of the rectum, which can lead
o loss of the rectum and anal canal, exhausting even the
est in clinical therapy, requiring proctectomy and permanent
stomy.
In summary, perianal CD is a common manifestation of the
isease and if it is concomitant to rectal lesions, the clinical
nd surgical management may become complex. Despite all
eveloped drugs and new surgical techniques, there is a failure
ate that is not negligible. Some cell therapies, such as MSCs,
nd new drugs that act upon other speciﬁc immune targets
ay be promising treatments for complex and/or recurrent
stulazing CD in the future.
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